July 6, 2015
The Ministry of Health, Labor and Welfare (MHLW) approved on July 3 Gilead Sciences K.K.’s oral genotype 1 chronic hepatitis C treatment Harvoni (ledipasvir + sofosbuvir). The health ministry also approved: Bristol-Myers K.K.’s Yervoy Injection 50 mg (recombinant ipilimumab), Nippon...read more